A clinical trial update on long term research carried out on patients with advanced gastro intestinal stromal tumours
10% of patients with advanced and aggressive GIST cancer have survived more than 10 years after treatment with one of the first successful targeted cancer drugs. They are living free of any progression of their cancer.
These are based on long-term results from a major international clinical trial of patients with advanced gastrointestinal stromal tumours (GIST) a decade after first taking the targeted drug imatinib, also known as Glivec.